Symposium 230 – Session I: New horizons in IBD etiopathogenesis
Chairs: Dominik Bettenworth, Muenster; Gerhard Rogler, Zurich
Duration: 118 min
Microbiota and microbiome in IBD: Pathogenetic relevance or therapeutic target?
Harry Sokol, Paris
New immunological pathways in IBD
Arthur Kaser, Cambridge
The new world of “Omics”: Will machine learning and artificial intelligence help?
Sana Syed, Charlottesville
Lost in translation: Does genetics have any impact for the IBD clinician?
Stefan Schreiber, Kiel
©Falk Foundation e.V., Freiburg. All rights reserved.
Early management of acute severe ulcerative colitis in the biologics era: A cohort study indicates that emergency colectomy rates have halved in the past 25 years to 8–15% worldwide. Patients not responding to corticosteroids may be readily identified on admission using a simple score consisting of serum C-reactive protein, albumin and an endoscopic activity score.
Rapid and sustained symptom relief in patients with ulcerative colitis treated with filgotinib: Post-hoc analysis of data from the SELECTION trial indicates that filgotinib therapy results in rapid and sustained improvements of symptoms related to ulcerative colitis within days.
Association of inflammatory bowel disease (IBD) and metabolic-associated fatty liver disease (MAFLD): A large recent case-control study demonstrates a significantly increased risk of MAFLD and liver fibrosis in IBD patients. This was independent of classic metabolic risk factors such as body mass index or type 2 diabetes.
Retreatment with immune checkpoint inhibitors after severe immune-related hepatitis: A current prospective study indicates that retreatment with immune checkpoint inhibitors is a feasible option after severe immune-related hepatitis, even with the same immune checkpoint inhibitors. There was no recurrence of liver injury in up to 65% of retreated patients.
Risk factors for hepatocellular carcinoma (HCC) in contemporary cohorts of patients with cirrhosis: In 2 contemporary, prospective multiethnic U.S. cohorts of patients with cirrhosis, HCC incidence was lower than previously reported. HCC risk was variable across etiologies, with higher risk in patients with hepatitis C-associated cirrhosis (even after cure of hepatitis C) and lower risk in those with cirrhosis due to non-alcoholic fatty liver disease. Smoking and obesity increased HCC risk.
Second-line eradication of Helicobacter pylori: In this randomized controlled trial, levofloxacin-based and bismuth-based quadruple therapies were equally effective to mediate eradication of Helicobacter pylori. The transient increase in the antibiotic resistome and perturbation of intestinal microbiota were largely restored to pretreatment states from 2 months to 1 year after eradication therapy.
Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: In a network metaanalysis, infliximab (5 mg/kg body weight) ranked first for induction of clinical remission in all patients, but risankizumab (600 mg) was first in biologic-naive and biologic-exposed patients. Upadacitinib (30 mg/day) ranked first for maintenance of remission.
Temporality of body mass index, blood tests, comorbidities and medication use as early markers for pancreatic ductal adenocarcinoma (PDAC): Risk of PDAC increased with raised HbA1c, liver markers, white blood cell and platelet counts and followed a U-shaped relationship for body mass index (BMI) and hemoglobin. BMI and HbA1c derange biphasically approximately 3 years while liver markers and blood counts derange monophasically approximately 1 year prior to diagnosis of PDAC. Profiling these markers in combination with their temporality could inform earlier diagnosis of PDAC.
Inflammation of the Upper and Lower GI Tract: Common mechanisms and Treatments or Important Differences?
April 28 – 29, 2023, Bordeaux, France
Online Live Event – Symposium 232: Inflammation of the Upper and Lower GI Tract: Common mechanisms and Treatments or Important Differences?
April 28. – 29, 2023
Experimental Hepatology Days
May 18 – 20, 2023, Zurich
Zurich Convention Center, Claridenstr. 5, 8002 Zurich, Switzerland
Mucosal Immunology – A Translational View into the Clinic
July 6 – 8, Potsdam, Germany
Dorint Hotel Sanssouci, Jägerallee 20, 14469 Potsdam, Germany